During treatment with Gleevec® (imatinib mesylate), you may be at risk for abnormally low blood cell counts, such as low red blood cells, white blood cells, or platelets, which can increase your risk for anemia, infection, and bleeding problems.
Your healthcare provider will monitor your blood counts with a simple blood test every week for the first month you are taking Gleevec, every other week during the second month, and then periodically for the remainder of treatment. If you develop problems with bleeding, your healthcare provider may need to reduce your dose or temporarily stop treatment.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click